EyePoint Pharmaceuticals (EYPT) News Today $5.68 +0.13 (+2.34%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$5.67 -0.01 (-0.18%) As of 04/17/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)April 16 at 7:00 AM | globenewswire.comVanguard Group Inc. Purchases 755,045 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Vanguard Group Inc. increased its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 24.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,803,227 shares of the company's stock after acquirApril 16 at 3:19 AM | marketbeat.comFederated Hermes Inc. Increases Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Federated Hermes Inc. increased its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 92.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,707,445 shares of the company's stock after acquiringApril 11, 2025 | marketbeat.comFinepoint Capital LP Grows Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Finepoint Capital LP boosted its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 57.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,111,104 shares of the company's stock aApril 8, 2025 | marketbeat.comSchroder Investment Management Group Purchases 146,403 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Schroder Investment Management Group raised its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 118.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 270,336 shares of the companyApril 8, 2025 | marketbeat.comFranklin Resources Inc. Purchases 125,519 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Franklin Resources Inc. lifted its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 3.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,137,567 shares of the company's stock after purchasing an additional 1April 7, 2025 | marketbeat.comHere's Why We're Watching EyePoint Pharmaceuticals' (NASDAQ:EYPT) Cash Burn SituationApril 2, 2025 | finance.yahoo.comCharles Schwab Investment Management Inc. Purchases 48,402 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Charles Schwab Investment Management Inc. boosted its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 33.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 191,165 shares of the companMarch 30, 2025 | marketbeat.comWhat is Chardan Capital's Estimate for EYPT FY2025 Earnings?EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Research analysts at Chardan Capital issued their FY2025 EPS estimates for shares of EyePoint Pharmaceuticals in a research report issued to clients and investors on Monday, March 24th. Chardan Capital analyst D. Gataulin forecasts thatMarch 28, 2025 | marketbeat.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of "Buy" from AnalystsEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has been assigned a consensus recommendation of "Buy" from the nine analysts that are presently covering the firm, MarketBeat reports. Nine research analysts have rated the stock with a buy recommendation. The average twelve-month pricMarch 28, 2025 | marketbeat.comWhat is Chardan Capital's Forecast for EYPT FY2026 Earnings?EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Chardan Capital issued their FY2026 EPS estimates for EyePoint Pharmaceuticals in a report issued on Monday, March 24th. Chardan Capital analyst D. Gataulin anticipates that the company will post earnings per share of ($2.82) for the yeMarch 27, 2025 | marketbeat.comEyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual ConferenceMarch 27, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and EyePoint Pharmaceuticals (EYPT)March 17, 2025 | markets.businessinsider.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)March 17, 2025 | globenewswire.comErste Asset Management GmbH Invests $360,000 in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Erste Asset Management GmbH bought a new position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 50,000 shares of the company's stock, valued at appMarch 16, 2025 | marketbeat.comStockNews.com Upgrades EyePoint Pharmaceuticals (NASDAQ:EYPT) to "Sell"StockNews.com upgraded shares of EyePoint Pharmaceuticals to a "sell" rating in a report on Friday.March 14, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and EyePoint Pharmaceuticals (EYPT)March 10, 2025 | markets.businessinsider.comResearch Analysts Set Expectations for EYPT FY2025 EarningsEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for EyePoint Pharmaceuticals in a research report issued on Thursday, March 6th. Cantor Fitzgerald analyst J. Kim now expects that the company will post earnings per sharMarch 10, 2025 | marketbeat.comQ1 EPS Estimate for EyePoint Pharmaceuticals Cut by AnalystEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Equities research analysts at HC Wainwright cut their Q1 2025 earnings per share estimates for shares of EyePoint Pharmaceuticals in a report released on Thursday, March 6th. HC Wainwright analyst Y. Chen now anticipates that the companMarch 10, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 7.4% - Here's What HappenedEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 7.4% - Here's What HappenedMarch 8, 2025 | marketbeat.comJonesTrading Remains a Buy on EyePoint Pharmaceuticals (EYPT)March 7, 2025 | markets.businessinsider.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Receives Buy Rating from Chardan CapitalChardan Capital reissued a "buy" rating and issued a $33.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday.March 7, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday.March 7, 2025 | marketbeat.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | msn.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Releases Earnings Results, Misses Estimates By $0.10 EPSEyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%.March 6, 2025 | marketbeat.comDespite Recent Gains, EyePoint Pharmaceuticals Insiders Are Still Down US$32kMarch 6, 2025 | finance.yahoo.comEyePoint Pharmaceuticals, Inc. (EYPT) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | seekingalpha.comEyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate DevelopmentsMarch 5, 2025 | globenewswire.comEyePoint Pharmaceuticals Q4 2024 Earnings PreviewMarch 4, 2025 | msn.comEyePoint Announces Participation at Upcoming Investor ConferencesMarch 4, 2025 | globenewswire.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of "Buy" from BrokeragesEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has been assigned an average rating of "Buy" from the nine analysts that are presently covering the company, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating. The average 12-month priceMarch 3, 2025 | marketbeat.comLevin Capital Strategies L.P. Purchases 44,000 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Levin Capital Strategies L.P. increased its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 440.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 54,000 shares of the company's stock afteMarch 2, 2025 | marketbeat.comEyePoint Pharmaceuticals (EYPT) Projected to Post Quarterly Earnings on ThursdayEyePoint Pharmaceuticals (NASDAQ:EYPT) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=670489)February 27, 2025 | marketbeat.comEYPT stock touches 52-week low at $5.9 amid sharp annual declineFebruary 26, 2025 | investing.comEyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025February 26, 2025 | globenewswire.comEyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | globenewswire.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Up 13.6% - Here's What HappenedEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 13.6% - Still a Buy?February 19, 2025 | marketbeat.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)February 17, 2025 | globenewswire.comabrdn plc Purchases Shares of 230,745 EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)abrdn plc acquired a new position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 230,745 shares of the company's stock, valued at approximately $1,719,00February 11, 2025 | marketbeat.comScotiabank Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)February 7, 2025 | markets.businessinsider.comChardan Capital Reaffirms Buy Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT)Chardan Capital restated a "buy" rating and issued a $33.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday.February 6, 2025 | marketbeat.comEyePoint Announces Positive 6-Month Data From Duravyu Trial For Diabetic Macular EdemaFebruary 6, 2025 | markets.businessinsider.comEyePoint stock jumps 10% on Duravyu study resultsFebruary 6, 2025 | msn.comEyePoint Pharmaceuticals Stock Gains 3% After Positive Phase 2 Trial ResultsFebruary 6, 2025 | markets.businessinsider.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by AnalystsEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has been assigned a consensus recommendation of "Buy" from the ten brokerages that are presently covering the firm, Marketbeat reports. Ten analysts have rated the stock with a buy recommendation. The average 1-year target price amongFebruary 6, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Reaches New 1-Year Low - Here's What HappenedEyePoint Pharmaceuticals (NASDAQ:EYPT) Reaches New 1-Year Low - Here's What HappenedFebruary 5, 2025 | marketbeat.comCollegium appoints Nancy Lurker to board of directorsFebruary 5, 2025 | markets.businessinsider.comDURAVYU shows promise in Phase 2 trial for eye diseaseFebruary 5, 2025 | msn.comEyePoint's decline following positive data makes no sense, says analystFebruary 5, 2025 | investing.comEyePoint Pharmaceuticals stock sinks following clinical trial resultsFebruary 5, 2025 | msn.com Get EyePoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address EYPT Media Mentions By Week EYPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EYPT News Sentiment▼1.110.49▲Average Medical News Sentiment EYPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EYPT Articles This Week▼24▲EYPT Articles Average Week Get EyePoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TXG News TRNS News CTKB News LAB News SENS News ALNT News AEHR News QSI News QTRX News FEIM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EYPT) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredThe Last Time Stocks Looked Like This, They Didn’t Move For 16 YearsThere is nothing the Federal Reserve can do to stop what's coming next for U.S. stocks. As you've seen your...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThey Won’t Tell You This About GoldInflation, digital currency, and government policy are quietly eating away at your savings — and most people w...American Alternative | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share EyePoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EYPT Stock Free EYPT Stock Alerts